MetaCap

uniQure N.V. (QURE) vs UroGen Pharma (URGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

UroGen Pharma (URGN) has outperformed uniQure N.V. (QURE) over the past year, gaining 6.9% versus a loss of 30.4%. Over five years, URGN leads with a +127.8% price change compared with -32.9% for QURE. uniQure N.V. is the larger company by market cap ($1.36 billion vs $1.36 billion), about 1.0 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs -40.6%).

UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -1236.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QURE-30.42%URGN+6.88%
+102%+13%-76%
Nov 21, 20251 yearNov 20, 2026
QURE-34.72%URGN+129.27%
+319%+106%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QURE versus URGN key metrics
MetricQUREURGN
Share price$19.35$27.65
Market cap$1.36B$1.36B
1-day change-4.35%-12.86%
YTD return-19.14%+18.06%
1-year return-30.42%+6.88%
5-year return-32.86%+127.76%
Forward P/E—11.08
EPS (TTM)$-3.51$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$16.10M$109.79M
Revenue growth (YoY)-40.64%+21.45%
Net income (latest FY)$-198.97M$-153.49M
Gross margin89.53%88.66%
Operating margin-1151.38%-113.73%
Net margin-1236.00%-139.81%
52-week high$51.72$50.81
52-week low$8.73$16.50
Distance from 52-week high-62.59%-45.58%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+207.03%+119.57%
Average volume2.26M1.11M
Shares outstanding70.14M49.05M
Employees221300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • URGN has outperformed QURE by 37.3 percentage points over the past year.
  • UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
  • UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs -40.64%).

About uniQure N.V.

QURE stock →

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees

About UroGen Pharma

URGN stock →

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees

QURE vs URGN FAQ

Which is bigger, uniQure N.V. or UroGen Pharma?

uniQure N.V. (QURE) is larger, with a market capitalization of $1.36B compared with $1.36B for UroGen Pharma (URGN).

Which stock has performed better over the past year, QURE or URGN?

URGN returned +6.88% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.

Are uniQure N.V. and UroGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons